MSD Animal Health highlights companion-animal innovation at WSAVA 2026

MSD Animal Health, known as Merck Animal Health in the United States and Canada, has announced a programme of scientific symposia and product showcases for the 2026 World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland. The company announcement was published on 12 October 2026.

The programme covers canine allergic dermatitis, parasite protection, and infectious-disease treatment and prevention. The company also highlighted NOBIVAC NXT feline vaccines, NUMELVI, BRAVECTO Injectable and the AFYA Programme’s rabies-elimination work.

A scheduled symposium on canine allergic dermatitis addresses diagnosis, differential assessment, multimodal treatment, pruritus control, skin-barrier restoration and year-round flea control. A separate session is planned around feline leukaemia virus (FeLV) and feline immunodeficiency virus (FIV). These sessions are intended to support clinical decision-making and continuing professional education.

Commercial significance

The announcement illustrates the continued importance of companion-animal medicine as a competitive segment of the global animal-health market. Product innovation is increasingly accompanied by clinical education designed to improve diagnosis, appropriate treatment selection and preventive-care adoption.

For manufacturers, veterinary congresses offer a platform to communicate scientific evidence, engage practitioners and demonstrate product portfolios. For veterinary practices, the practical value depends on the strength of the underlying clinical evidence, suitability for individual patients, local authorisation status and affordability.

The company’s announcement should not be interpreted as evidence that every product mentioned is newly approved in every market. Product availability and authorised indications differ by jurisdiction, and the symposium programme itself is not a regulatory approval.

Industry outlook

The focus on dermatology, parasite prevention, feline infectious disease and vaccination demonstrates how pharmaceutical innovation, clinical education and preventive healthcare are being combined to strengthen companion-animal treatment pathways.